Search


PDF Archive search engine
Last database update: 28 November at 17:16 - Around 76000 files indexed.


Show results per page

Results for «pharmaceutical»:


Total: 100 results - 0.05 seconds

ra'ed 100%

Eastern Mediterranean Pharmaceutical Symposium 2016 External Communication Chairperson of the International Pharmaceutical Student's Federation's Eastern Mediterranean Pharmaceutical Symposium 2016 in Egypt.

https://www.pdf-archive.com/2016/12/27/ra-ed/

27/12/2016 www.pdf-archive.com

WHO trs 992 98%

992 W H O Te c h n i c a l R e p o r t S e r i e s 992 WHO Expert Committee on Specifications for Pharmaceutical Preparations WHO Technical Report Series The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines.

https://www.pdf-archive.com/2016/03/06/who-trs-992/

06/03/2016 www.pdf-archive.com

Builder 8607 Professional Printing[1] 95%

Dohme, NJ Why it Matters While Portugal represents a relatively small export market for the United States, major innovative pharmaceutical companies, including MSD, have had a significant presence there during the last decade.

https://www.pdf-archive.com/2014/07/18/builder-8607-professional-printing-1/

18/07/2014 www.pdf-archive.com

FDA Laws and Drug Prices AAPS 94%

Is Excess Regulation Responsible For Soaring Pharmaceutical Prices?

https://www.pdf-archive.com/2016/08/25/fda-laws-and-drug-prices-aaps/

25/08/2016 www.pdf-archive.com

Hearing Conservation Programme for shopfloor 92%

听力保护计划 West Pharmaceutical Services Singapore Pte Ltd 1 Objective 目标 The objective of the program is to identify and control noise hazards and protect all employees who have a potential to develop noise induced hearing loss.

https://www.pdf-archive.com/2014/05/08/hearing-conservation-programme-for-shopfloor/

08/05/2014 www.pdf-archive.com

2017 Reimbursmenet of eHealth solutions 89%

Pharmaceutical companies are aware of this opportunity and are looking at ways in which these types of technologies can complement their products to offer “beyond the pill” solutions.

https://www.pdf-archive.com/2017/11/11/2017-reimbursmenet-of-ehealth-solutions/

11/11/2017 www.pdf-archive.com

PHARMA LIBITUM REGISTRATION FORM 86%

PHARMA LIBITUM 2013 REGISTRATION FORM CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, GUNTUR Symposium Outline  NAME EDUCATIONAL QUALIFICATION  ADDRESS  E-MAIL MOBILE  E-POSTER TITLE  PHARMA LIBITUM On 30th March – 2013 Organized by Dept.

https://www.pdf-archive.com/2013/03/05/pharma-libitum-registration-form/

05/03/2013 www.pdf-archive.com

Marion-D-S-Dreyfus (1) 86%

DREYFUS 155 West 68th Street • New York, NY 10023• dreyfusmarion@hotmail.com • […] […] PROFESSIONAL SUMMARY Diverse management expertise developed through broad background in writing and media, to function as pharmaceutical/healthcare/documentation writer, editor, content manager, regulatory-documentation, PR/ advertising;

https://www.pdf-archive.com/2015/08/28/marion-d-s-dreyfus-1/

28/08/2015 www.pdf-archive.com

file 85%

https://www.pdf-archive.com/2017/05/18/file/

18/05/2017 www.pdf-archive.com

SWEnewsletterFall2013 85%

If you are interested in mentoring a freshman or seeking an alumna as a mentor, email us at swe.drexel@gmail.com Teva Pharmaceuticals On October 3, 2013, Drexel SWE had the privilege and pleasure of hosting Teva Pharmaceutical Industries LTD.

https://www.pdf-archive.com/2013/12/23/swenewsletterfall2013/

23/12/2013 www.pdf-archive.com

Programme Information 84%

Programme Information PhD Fellowship at Florida A&M University/USA Application requirements • The applicant must be Brazilian • Bachelor’s in Pharmaceutical Sciences • Master completed in Pharmaceutical Sciences less than five years before the beginning of the fellowship (January 2018) • Initial proven leadership experience;

https://www.pdf-archive.com/2017/12/14/programme-information/

14/12/2017 www.pdf-archive.com

The Insys Enforcement Action Scorecard v2.0 20170203 84%

https://www.justice.gov/usao-ma/pr/pharmaceutical-executives-charged-racketeering-scheme 2.

https://www.pdf-archive.com/2017/02/04/the-insys-enforcement-action-scorecard-v2-0-20170203/

03/02/2017 www.pdf-archive.com

05112015 TPP - IP chapter complete 83%

    4 August 2015  FOR IMMEDIATE RELEASE  CONTACT: Zack Struver  +1 (202) 332­2670  zack.struver@keionline.org      Knowledge Ecology International Leaks TPP Text on Intellectual  Property    Tuesday, August 4th, 2015    Washington, DC — Today, August 4, 2015, Knowledge Ecology International (KEI) released  text from three sections of the 95­page secret negotiating text on the Intellectual Property  Chapter being used in the Trans­Pacific Partnership Agreement (TPP, sometimes referred to as  TPPA) trade negotiations. The negotiating text is dated May 11, 2015, and reflects the state of  the text right before the Maui rounds of the negotiation, which ended Friday, July 31, 2015.    Released this morning is text from the following sections of the IP Chapter:    ● All of Section B on Cooperation.  (Pages 8 to 10 of the IP Chapter)  ● All of Section E on “Patents / Undisclosed Test or Other Data / Traditional Knowledge.”  (Pages 29 to 53 of the IP Chapter)  ● Articles 1 through 11 from Section H on enforcement. (Pages 67 through 89 of the IP  Chapter)    We hope to release the remaining sections (A, C, D, F, G, and the rest of H) later today and  Wednesday.    The text will be placed on this web page:  ​ http://keionline.org/tpp/11may2015­ip­text    The text released this morning is most relevant to issues related to pharmaceuticals, especially  rules on biologics and new chemicals. Later today or tomorrow, KEI will release sections of the  text relevant to copyright and trademarks.    KEI will publish a more detailed analysis of the text later. James Love, Director of Knowledge  Ecology International, released the following statement this morning:    “KEI is publishing the consolidated text for the TPP IP Chapter from May 11, 2015, in  order to enable the public to understand, analyze, and influence the rules that have been  proposed for intellectual property in this important trade negotiation.  Over 600 corporate  advisors already have access to this text, and this leak, at least temporarily, levels the  field somewhat (there will be a new text coming out of last week’s talks in Maui).    The May 11, 2015, text includes country positions, and reveals extensive disagreements  among parties, as well as the isolation of the United States as the country that continues  to be the most aggressive supporter of expanded intellectual property rights for drug  companies, publishers and other companies.    The proposals contained in the TPP will harm consumers and in some cases block  innovation. In countless ways, the Obama Administration has sought to expand and  extend drug monopolies and raise drug prices. The astonishing collection of proposals  page 1 of 4 pandering to big drug companies make more difficult the task of ensuring access to drugs  for the treatment of cancer and other diseases and conditions.    The widely reported dispute over the number of years of protection for biologic drug test  data is only one of dozens of measures that significantly expand the power of big drug  companies to charge high prices. Taken together these provisions will take the public  down a road of more and more rationing of medicines, and less and less equality of  access.  It could have and still can be different. Rather than focusing on more intellectual  property rights for drug companies, and a death­inducing spiral of higher prices and  access barriers, the trade agreement could seek new norms to expand the funding of  medical R&D as a public good, an area where the United States has an admirable track  record, such as the public funding of research at the NIH and other federal agencies.  Many people reading the provisions released today will appreciate how misguided and  wrong are the USTR’s values and negotiating objectives.”    James Love, Director, KEI, August 4, 2015    For more information and perspectives, we are also attaching the names and contact information  for several persons who can comment on the text released this morning, including health and  consumer group NGOs, academics, and industry experts.     Health and consumer group NGOs    Knowledge Ecology International  ● ● ● James Love, Director, +1.202.361.3040, james.love@keionline.org  Andrew S. Goldman, Counsel for Policy & Legal Affairs, +1.202.332.2670,  andrew.goldman@keionline.org  Thiru Balasubramaniam, Geneva Representative, thiru@keionline.org, +41 22 791 6727    Public Citizen  ● ● Peter Maybarduk, Director, +1.202.588.7755, pmaybarduk@citizen.org  Burcu Kilic, Research Director, +1.202.588.7792, bkilic@citizen.org    Doctors Without Borders/Médecins Sans Frontières  ● Judit Rius Sanjuan, U.S. Manager & Legal Policy Adviser, Access Campaign, T:  +1.212.655.3762, M: +1.917.331.9077, Judit.Rius@newyork.msf.org     Academics    Professor Susan K. Sell  Elliott School of International Affairs  George Washington University  T: (202) 994­4896  susan.sell@gmail.com    Professor Kevin Outterson  Boston University School of Law  mko@bu.edu    Dr. Deborah Gleeson  Department of Public Health  La Trobe University  Melbourne, Australia  T: +61 3 9479 3262  M: +61 423 209029  deborah@gleeson.net    Professor Margot Kaminski  page 2 of 4 Moritz College of Law  Ohio State University  margot.kaminski@gmail.com    Professor Brook K. Baker  Program on Human Rights and the Global Economy  Northeastern University School of Law  T: (617) 373=3217  M: (617) 259­0760  b.baker@neu.edu    Dr. Ruth Lopert  Department of Public Health  George Washington University  (202) 415­7726  rlopert@gwu.edu    Pharmaceutical and biotechnology industry experts who are familiar with the TPP IP  Chapter     Joseph Damond  Senior Vice President, International Affairs  Biotechnology Industry Organization (BIO)  jDamond@bio.org    Members of USTR’s Industry Trade Advisory Committees (ITAC)    ITAC 15: Industry Trade Advisory Committee on Intellectual Property Rights    Gregg H. Alton, Esq.  Executive Vice President, Corporate and Medical Affairs, Secretary and Chief Compliance Officer  Gilead Sciences, Inc.    Paul A. Coletti  Associate Patent Counsel  Johnson & Johnson    Erik H. Iverson, Esq.  President, Business and Operations  Infectious Disease Research Institute    Mr. Richard H. Kjeldgaard  Consultant  Representing Pharmaceutical Research and Manufacturers of America    Jeffrey P. Kushan, Esq.  Sidley Austin  Representing Biotechnology Industry Organization    Jonathan L. Marks, Esq.  Vice President, International Affairs  Generic Pharmaceuticals Association    ITAC 3: Industry Trade Advisory Committee On Chemicals, Pharmaceuticals,  Health/Science Products And Services    Ms. Tiffany McCullen Atwell  Director, International Government Affairs  DuPont Government Marketing and Government Affairs  E.I. du Pont de Nemours and Company  page 3 of 4   Mr. Harrison C. Cook  Vice President, International Government Affairs  Eli Lilly and Company    Mr. Ralph F. Ives  Executive Vice President, Global Strategy and Analysis  AdvaMed: Advanced Medical Technology Association     Mr. Maurice J. Kerins  President  Airmed Biotech, Inc.    Douglas T. Nelson, Esq.  Senior Advisor for Trade, Intellectual Property and Strategic Affairs  CropLife America    Mr. Paul A. Neureiter  Executive Director, Government Affairs  Amgen Inc.    Mr. James R. Plante  Founder and Chief Executive Officer  Pathway Genomics    Ms. Lisa M. Schroeter  Global Director, Trade and Investment Policy  The Dow Chemical Company   ###  page 4 of 4

https://www.pdf-archive.com/2015/08/06/05112015-tpp-ip-chapter-complete/

06/08/2015 www.pdf-archive.com

PHARMA LIBITUM REGISTRATION FORM 82%

PHARMA LIBITUM 2013 REGISTRATION FORM CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, GUNTUR Symposium Outline  NAME EDUCATIONAL QUALIFICATION  ADDRESS  E-MAIL MOBILE  E-POSTER TITLE  PHARMA LIBITUM On 30th March – 2013 Organized by Dept.

https://www.pdf-archive.com/2013/03/07/pharma-libitum-registration-form/

07/03/2013 www.pdf-archive.com

WADA 78%

In this letter CPJ expresses their concern about corruption actions inside international sports organizations and regulatory and control authorities, provoking unfair competition among pharmaceutical companies by their means, and threats and persecution of the journalists covering this issue.

https://www.pdf-archive.com/2016/04/15/wada/

15/04/2016 www.pdf-archive.com

wada2 78%

media@wada-ama.org Dear President Reedie, The Committee to Protect Journalists, an independent nonprofit organization promoting press freedom worldwide, is writing to express its enduring concern over the corruption component in international sports organizations, regulating and supervising organs, and employing them as tools of unfair competition among the pharmaceutical companies.

https://www.pdf-archive.com/2016/04/22/wada2/

22/04/2016 www.pdf-archive.com

StudentHandbook 77%

College of Pharmacy Student Handbook 2017-2018 Table of Content President’s Message 5 Dean’s Message 6 Welcome to Students 7 College of Pharmacy Vision Statement 7 College of Pharmacy Mission Statement 7 Equal Education and Employment Statement 8 College of Pharmacy Administration and Departmental Information 9 Dean’s Office Office of Academic Affairs Office of Student Affairs Department of Pharmaceutical Sciences Department of Pharmacy Practice Office of Experiential &

https://www.pdf-archive.com/2018/02/06/studenthandbook/

06/02/2018 www.pdf-archive.com

chase pdf att2 76%

Established relationships with pharmaceutical &

https://www.pdf-archive.com/2012/07/10/chase-pdf-att2/

10/07/2012 www.pdf-archive.com

107172 A4 SUPERBUG CRISIS v3 76%

Glasgow Science Festival 2017 8th - 18th June Pharmaceutical Rep Nurse Doctor Scientist Parent Pet-owners Farmer Whose Superbug Crisis is it anyway?

https://www.pdf-archive.com/2017/05/23/107172-a4-superbug-crisis-v3/

23/05/2017 www.pdf-archive.com

Programme Information. postdoctoral 76%

Application requirements • Bachelor’s in Pharmaceutical Sciences • PhD completed in Pharmaceutical/Biomedical Sciences less than five years before the beginning of the fellowship (January 2018) • Initial proven leadership experience;

https://www.pdf-archive.com/2017/12/14/programme-information-postdoctoral/

14/12/2017 www.pdf-archive.com

ISPOR MEMBERSHIP FORM PDF 76%

ISPOR – INDIA- AMARAVATI REGIONAL CHAPTER Chalapathi Institute of Pharmaceutical Sciences (Autonomous) Accredited by NAAC with ‘A’ grade Membership Form Name:__________________________________________ Age:

https://www.pdf-archive.com/2018/02/14/ispor-membership-form-pdf/

14/02/2018 www.pdf-archive.com

Brandon May Freelance Writer CV 76%

Skills l l l l l Ability to meet tight deadlines Knowledge of AMA Style Understanding of current SEO tactics Marketing copy for pharmaceutical companies Content development for print and web l l l l Ability to utilize research databases Capable of analyzing and synthesizing pertinent medical literature into coherent documentation Strong ability to match the voice and style of a company Passion for research as a means for developing accurate copy Organizations American Medical Writers Association, 2014 National Association of Sciences Writers, 2015 Professional Experience Haley Marketing Group – B2B Marketing Agency Staffing and Recruiting Marketing Writer · Blogger · (2012 - 2014) ñ Delivering high-quality, deadline-oriented B2B posts geared toward the company’s staffing and recruiting client ñ Composed engaging and informative blog posts for professionals (physicians, nurses, pharmacists, etc.) seeking employment and staffing agencies ñ Freelance writer and blogger for healthcare staffing companies and job seekers ñ Social media manager, creating promotional and technical materials for clients, including:

https://www.pdf-archive.com/2016/04/11/brandon-may-freelance-writer-cv/

11/04/2016 www.pdf-archive.com

CarolynJarvis - Resume 75%

Counted, priced and inventoried pharmaceutical drugs.

https://www.pdf-archive.com/2016/05/11/carolynjarvis-resume/

11/05/2016 www.pdf-archive.com

Mallinkrodt 75%

A B D 29.722 OD P 2"

https://www.pdf-archive.com/2016/07/20/mallinkrodt/

19/07/2016 www.pdf-archive.com

DDND-2012-Program-low-res 75%

Subsequent to the ADDF’s critical initial seed funding, our grantees have received additional follow-on funding from government, pharmaceutical companies and venture capital firms in excess of $2 billion to further advance their drug research.

https://www.pdf-archive.com/2016/11/04/ddnd-2012-program-low-res/

04/11/2016 www.pdf-archive.com